1. Pink Sheet
  2. >>Geography
  3. >>North America
  4. >>United States

Pharmacyclics/Janssen Offer Suite Of Patient Support Programs For Imbruvica

 
• By Wendy Diller

With a monthly cost of $10,900/month for the ultra-rare disease mantle cell lymphoma, Pharmacyclics and Janssen are being proactive about patient aid with a 30-day offer while reimbursement is worked out, as well as other support offerings that have become part of the new reality for high-priced oncologics.

That Pharmacyclics Inc./Janssen Biotech Inc. are launching their hematological cancer drug ibrutinib with a patient financial support program is to be expected. But the multiple approaches and tandem programs being offered show how extensive these programs must be as drugs with six-figure price tags grapple with reimbursement realities.

Imbruvica (ibrutinib) is the first Bruton’s tyrosine kinase inhibitor and the second breakthrough therapy to receive FDA approval. It was...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from United States

Podium Policy Returns To US FDA, Or Is It Podcast Policy?

 
• By Michael McCaughan

US FDA critics have long decried the practice of using informal communications to convey regulatory expectations as podium policy. In the Makary era, the phrase may need to be updated because the agency now seems to be specializing in policy by podcast.

US FDA’s Elsa AI Platform Is Not Guiding Regulatory Decisions, Official Says

 
• By Cathy Kelly

Tala Fakhouri said the agency’s use of the AI tool in the review process has generated lots of questions.

Branch Chief Vijay Kumar Named Acting Head Of US FDA’s Cell, Gene Therapy Office

 
• By Derrick Gingery

Kumar takes over as acting director of the Center for Biologics Evaluation and Research’s Office of Therapeutic Products days after director Nicole Verdun was ousted.

Recent And Upcoming FDA Advisory Committee Meetings

 
• By Sue Sutter

Recent and upcoming US FDA advisory committee meetings and a summary of the topics covered.

More from North America

BIO Notebook: Policy Uncertainty Constraining Dealmaking

 
• By Mandy Jackson and Joseph Haas

Highlights from Day Four of the BIO International Convention include policy concerns helping constrain dealmaking, Novartis discussing its approach to partnering, and Generate looking for funding to move into Phase III.

Woodcock: Do Not Do The Wrong Study, Even If Against US FDA Advice

 
• By Sarah Karlin-Smith

The former CDER director said she tells sponsors not to conduct an FDA-recommended study design or randomized trial if it will not work.

AI Will Bolster, Not Squelch, Patient Voice In Clinical Research, US FDA Says

 
• By Sue Sutter

Artificial intelligence tools used for clinical research should be developed with input from patients and focus on their needs and abilities, FDA experts said.